Edwards Lifesciences Quarterly Balance Sheet
NYSE: EWHealth CareIndustrial SpecialtiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Edwards Lifesciences financial position
As of Jun 30, 2026, Edwards Lifesciences reported total assets of $13.87 billion, up 2.8% from a year earlier against total liabilities of $3.14 billion. Shareholders' equity stood at $10.62 billion, or 76.6% of assets. The company held $2.91 billion in cash and equivalents against $598.7 million of debt, a net cash position of $2.31 billion.
The current ratio (current assets divided by current liabilities) was 4.52, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.06.
Summary generated from market data by MetaCap's automated system. Methodology
Edwards Lifesciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.91B | 2.45B | 2.94B | 2.69B | 3.27B | 3.14B | 3.05B | 3.68B | 1.64B | 1.22B | 1.13B | 1.41B |
| Short-Term Investments | 1.35B | 1.23B | 1.29B | 1.16B | 789.40M | 757.90M | 930.70M | 769.70M | 345.30M | 473.00M | 500.50M | 453.80M |
| Receivables | 770.40M | 775.70M | 659.60M | 693.30M | 697.00M | 669.20M | 609.10M | 716.00M | 778.30M | 817.60M | 771.50M | 739.80M |
| Inventory | 1.13B | 1.12B | 1.13B | 1.14B | 1.14B | 1.11B | 1.09B | 1.10B | 1.02B | 1.21B | 903.50M | 1.03B |
| Total Current Assets | 6.82B | 6.23B | 6.74B | 6.36B | 6.58B | 6.21B | 6.29B | 6.73B | 4.52B | 4.17B | 4.04B | 4.07B |
| Property, Plant & Equipment | 1.84B | 1.82B | 1.81B | 1.74B | 1.73B | 1.70B | 1.69B | 1.68B | 1.64B | 1.77B | 1.59B | 1.68B |
| Goodwill | 1.95B | 1.82B | 1.77B | 1.77B | 1.78B | 1.78B | 1.78B | 1.61B | 1.15B | 1.25B | 1.15B | 1.30B |
| Intangible Assets | 1.38B | 1.23B | 1.13B | 1.13B | 1.17B | 1.17B | 1.18B | 956.10M | 417.10M | 446.80M | 399.40M | 429.80M |
| Long-Term Investments | 244.10M | 285.60M | 278.60M | 274.70M | 298.50M | 277.90M | 307.90M | 319.60M | 353.30M | 455.60M | 583.90M | 704.60M |
| Total Assets | 13.87B | 13.32B | 13.70B | 13.27B | 13.49B | 13.02B | 13.06B | 12.97B | 10.10B | 9.74B | 9.36B | 9.37B |
| Accounts Payable | 210.50M | 181.10M | 227.50M | 165.00M | 162.10M | 172.40M | 197.40M | 172.80M | 185.90M | 212.30M | 186.60M | 190.60M |
| Total Current Liabilities | 1.51B | 1.41B | 1.81B | 1.59B | 1.40B | 1.39B | 1.51B | 1.94B | 1.22B | 1.11B | 1.20B | 1.24B |
| Long-Term Debt | 598.70M | 598.50M | 598.30M | 598.20M | 598.00M | 597.80M | 597.70M | 597.50M | 597.30M | 597.20M | 597.00M | 596.80M |
| Total Liabilities | 3.14B | 2.99B | 3.36B | 3.07B | 2.88B | 2.83B | 2.99B | 3.36B | 2.59B | 2.55B | 2.64B | 2.64B |
| Shareholders' Equity | 10.62B | 10.33B | 10.34B | 10.21B | 10.55B | 10.13B | 10.00B | 9.55B | 7.44B | 7.12B | 6.65B | 6.66B |
| Retained Earnings | 14.86B | 14.62B | 14.24B | 14.15B | 13.86B | 13.53B | 13.17B | 12.78B | 9.71B | 9.34B | 8.99B | 8.62B |
| Total Debt | 598.70M | 598.50M | 598.30M | 598.20M | 598.00M | 597.80M | 597.70M | 597.50M | 597.30M | 597.20M | 597.00M | 596.80M |
| Net Cash (Debt) | 3.65B | 3.07B | 3.63B | 3.24B | 3.46B | 3.30B | 3.38B | 3.85B | 1.39B | 1.10B | 1.04B | 1.27B |
| Shares Outstanding | 576.60M | 577.00M | 580.70M | 580.70M | 587.90M | 586.20M | 588.60M | 589.80M | 602.30M | 602.40M | 601.10M | 606.50M |
This table shows 12 quarterly periods of Edwards Lifesciences's balance sheet, from Q2 2026 back to Q3 2023, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow EW's reporting calendar. What is a balance sheet?